Rheumatoid arthritis, even riskier in cases of obesity

What it means in practice

For patients and healthcare professionals, the practical message is to recognize obesity as a condition associated with worse outcomes in rheumatoid arthritis, without, however, transforming the association into an automatic cause-and-effect relationship. In the clinical context, this means systematically assessing weight and body composition as part of the patient's overall evaluation (for example, to identify cardiovascular comorbidities), considering the impact of weight on pain perception and functional measures, and carefully discussing shared treatment goals.

Multidisciplinary interventions that include nutritional support, adapted physical activity, and pain management can improve quality of life, metabolic parameters, and, in some studies, reduce disease activity. However, the choice of pharmacological therapies should not be based solely on BMI: the set of clinical characteristics, patient preferences, and available evidence on the relationship between adiposity and response to the individual drug must be considered.

Obesity and risk of onset

Cohort studies and meta-analyses document an association between high BMI and an increased risk of AR onset, with an increased risk for every 5 kg/m2 increase in BMI in some studies [1][2]. The evidence is more consistent in women; however, the observational nature of the studies does not allow us to state with certainty that obesity is a direct causal factor, although genetic studies offer supporting evidence.

Obesity, disease severity, and response to therapies

Recent meta-analyses show that people with obesity are less likely to achieve remission and report worse disease activity scores and quality of life during follow-up [3]. Some systematic reviews also highlight that excess weight compromises the response to anti-TNF agents, while the impact on other agents (e.g., tocilizumab, abatacept) is less clear [4].

Role of diet and weight loss

Interventions aimed at weight loss or diets with anti-inflammatory components have shown improvements in clinical parameters and biomarkers in randomized and crossover studies; a weight loss trial reported reductions in disease activity in obese subjects with AR [5], and structured diets (Mediterranean / "anti-inflammatory" type) have improved lipid profiles and some clinical indicators [6]. Larger and longer-term studies are needed to confirm sustained effects and translate the results into operational recommendations.